Insulin analog

from Wikipedia, the free encyclopedia

An insulin analog (also called artificial insulin or analog insulin ) is an artificially produced, patented protein (insulin derivative, insulin derivative ) that is structurally and functionally related to human insulin in terms of its blood sugar lowering effect . The most varied of pharmaceutically active insulin analogs (insulin analogs = plurality of insulin analogs) were produced by the insulin industry and brought onto the market. Insulin analogues are intended to compensate for the disadvantages of previous insulin preparations in the treatment of diabetes mellitus - currently insulin analogues with faster and shorter effects as well as those with longer effects are used. Insulin analogs are produced using genetic engineering. Their application security was questioned early on. Their therapeutic superiority has not been clearly demonstrated. Their higher prices (compared to unmodified natural insulin) and the resulting increased financial burdens for patients and health insurance companies are clearly proven. Various different biological effects compared to natural insulin have also been proven.

Individual evidence

  1. ↑ Georg Löffler, Petro E. Petrides, Peter C. Heinrich (Eds.): Biochemistry and Pathobiochemistry . 8th edition. Springer, Heidelberg 2007, ISBN 978-3-540-32681-6 , pp. 816 f ., Doi : 10.1007 / 978-3-540-32681-6 .
  2. ↑ E. Chantelau: Concealed concerns . Is artificial insulin dangerous? Questions to the Düsseldorf diabetologist Ernst Chantelau. In: Carl Schüddekopf (Ed.): Die ZEIT . No. 48 . Hamburg November 20, 2003.
  3. ↑ Kasia J. Lipska: Insulin Analogues for Type 2 Diabetes . In: JAMA . tape 321 , no. 4 , 2019, p. 350–351 , doi : 10.1001 / jama.2018.21356 .
  4. ^ Kristin Eckardt, Jürgen Eckel: Insulin analogues: Action profiles beyond glycaemic control . In: Archives of Physiology and Biochemistry . tape 114 , no. 1 , 2008, p. 45-53 , doi : 10.1080 / 13813450801983369 .
  5. ↑ Hansen BF, Kurtzhals P, Jensen AB, Dejgaard A, Russell-Jones D: Insulin X10 revisited: a super-mitogenic insulin analogue . In: Diabetologia . tape 54 , 2011, p. 2226-2231 .
  6. ^ Haim Werner, Ernst-A. Chantelau: Differences in bioactivity between human insulin and insulin analogues approved for therapeutic use - compilation of reports from the past 20 years. In: Diabetology & Metabolic Syndrome Vol. 3 (13). 2011, accessed July 29, 2020 .
  7. ^ Haim Werner, Doron Weinstein, Einat Yehezkel & Zvi Laron: Controversies in the use of insulin analogues. In: Expert.Opin.Biol.Ther. 2011: 11 (2). 2011, pp. 199–209 , accessed on July 29, 2020 .
  8. ↑ Laura Sciacca, Rosario Le Moli and Riccardo Vigneri: Insulin analogs and cancer. In: Front. Endocrinol. February 10, 2012, accessed July 29, 2020 .